FilingReader Intelligence
Zydus gets US approval for heart drug tablets
August 11, 2025 at 04:49 AM UTC•By FilingReader AI
Zydus Lifesciences Limited received final US Food and Drug Administration approval for its Diltiazem Hydrochloride Tablets in four strengths. The heart medication treats chronic stable angina and coronary artery spasm.
The tablets had annual US sales of $13.9 million according to IQVIA data. This brings Zydus's total approvals to 423.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
BSE:ZYDUSLIFE•Bombay Stock Exchange
News Alerts
Get instant email alerts when Zydus Lifesciences publishes news
Free account required • Unsubscribe anytime